Tramadol's analgesic mechanism differs from classical opioids. A patient with a CYP2D6 ultra-rapid metabolizer (UM) genotype is at increased risk of which adverse outcome when taking tramadol?

• A Therapeutic failure due to excessive tramadol conversion to inactive N-desmethyltramadol
• B Serotonin syndrome from excessive serotonin reuptake inhibition without balanced μ-receptor effect
• C Life-threatening opioid toxicity due to rapid conversion of tramadol to its active metabolite O-desmethyltramadol (M1), which has 200× higher μ-opioid affinity than tramadol ✓
• D Seizures due to overflow of the parent compound into the CNS at ultra-rapid conversion rates

Explanation

Tramadol exerts analgesia via two mechanisms: (1) weak μ-opioid agonism (parent compound), and (2) inhibition of norepinephrine and serotonin reuptake. Its O-desmethylation by CYP2D6 generates M1 (O-desmethyltramadol), which has approximately 200-fold higher μ-opioid affinity than the parent compound. CYP2D6 ultra-rapid metabolizers (carrying CYP2D6 gene duplications, common in North African and Middle Eastern populations ~10–29%) produce M1 excessively quickly, causing opioid overdose with respiratory depression despite standard doses. This is the same mechanism as codeine toxicity in UM patients. The FDA black box warning on tramadol specifically mentions this risk in CYP2D6 UMs and in nursing infants whose mothers take tramadol.

Reference: KD Tripathi, Essentials of Medical Pharmacology, 8th ed.

High-yield for: NEET PGINI-CETNExTFMGEUSMLEPLABMRCP

Written and medically reviewed by the StethoPrep medical team.